Safety Evaluation of DREPADOM - Home Care Services and Hospitalizations for Sickle Cell Disease Patients

NCT05649280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-12-14

No results posted yet for this study

Summary

The objective of this study is to evaluate the incidence of ACS within the DREPADOM system and compare it to expected incidences of ACS (historic cohorts of PRESEV1 and PRESEV2)

Conditions

Sponsors & Collaborators

  • Soutien aux Actions contre les Maladies du Globule Rouge

    lead OTHER

Principal Investigators

  • Pablo BARTOLUCCI, PROFESSOR · Soutien aux Actions contre les Maladies du Globule Rouge

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-02-01
Completion
2022-06-01

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05649280 on ClinicalTrials.gov